Cost-benefit evaluation of drug treatment for Alzheimer's disease
| Autor: | S. Kanowski |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Drug
Aging medicine.medical_specialty Health (social science) Scope (project management) business.industry Institutionalisation media_common.quotation_subject Disease medicine.disease Drug treatment Pharmacotherapy Medicine Dementia Cost benefit Geriatrics and Gerontology business Psychiatry Gerontology media_common |
| Zdroj: | Archives of Gerontology and Geriatrics. 26:275-280 |
| ISSN: | 0167-4943 |
| DOI: | 10.1016/s0167-4943(98)80039-3 |
| Popis: | Summary On the background of an ongoing discussion on the cost-benefit relation of nootropic drugs, the whole scope and the dimensions of the problem have to be considered. This will be done with a short view on diagnostics as a prerequisit of proper treatment. Then a comprehensive treatment program has to be outlined demonstrating that drug therapy can be only one factor in alleviating the burden of patients and their families. Against that background the results of a few types of experimental, “quasi” experimental and theoretical studies will be reported which give some evidence that drug induced improvement is economically effective. The main outcome criteria which should be used are: Slowing of progression of dementia process, avoidance or postponing of longterm institutionalization, alleviation of the burden, and the amount of needed support by caregivers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect